Clinical trials: Cancer Liver
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Predictive Cancer Model
Prospective Validation of Liver Cancer Risk Computation (LIRIC) Models
The goal of this prospective observational cohort study is to validate previously developed Hepatocellular Carcinoma (HCC) risk prediction algorithms, the Liver Risk Computation (LIRIC) models, which are based on electronic…
- Trial name
- NCT06140823
- Testing
- Liver Risk Computation Model (LIRIC), Liver Risk Computation Model (LIRIC)_cirrhosis, Liver Risk Computation Model (LIRIC)_no_cirrhosis
- Where
- United States
- Volunteers
- 6,000,000 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Colorectal Cancer Metastatic
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.
- Trial name
- NCT06283303
- Testing
- T3011 hepatic artery infusion, toripalimab, regorafenib
- Volunteers
- 8 people
- Sponsor
- China Medical University, China
Radiotherapy, Immunotherapy
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
This study is a randomized controlled phase II trial to evaluate the efficacy of the combination of stereotactic body radiation therapy (SBRT) and immunotherapy with postoperative chemotherapy in colorectal cancer liver…
- Conditions
- Radiotherapy, Immunotherapy, Liver Metastases, Colorectal Cancer
- Trial name
- IMPROVE (NCT06120127)
- Testing
- SBRT, Chemotherapy, PD-1 antibody
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Adjuvant Radiotherapy Comparing TACE for Curative HCC
Despite advances in our understanding of hepatocellular carcinoma (HCC) and its diagnosis, the prognosis for patients with HCC remains disheartening, due to a high recurrence rate and frequent intrahepatic metastasis.
- Trial name
- ARTC-HCC (NCT02125396)
- Testing
- Transarterial chemoembolization, Radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma, Liver Transplant Disorder
Liver Transplant for Larger Hepatocellular Carcinoma in Malatya: The Role of GGT and AFP
Retrospective data on 50 prospectively-collected HCC patients with beyond-Milan criteria with >6cm tumors were analyzed. 5-year OS of 76.2% was found in patients with both AFP <200 ng/ml and GGT <104 IU/mL with tumors less than…
- Trial name
- NCT04412161
- Testing
- Liver transplantation
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Inonu University
Primary Liver Cancer
The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer
Supplementation of BCAA found to reduce the risk of developing liver cancer, but the affect of BCAA on existing liver cancer is unknown.
- Trial name
- NCT02327819
- Testing
- Branched-chain amoni acids (BCAA), non-BCAA protein supplement
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Colon Cancer, Esophageal Carcinoma
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
The purpose of this study is to evaluate the safety and efficacy of EpCAM-specific CAR T Cells infusion for EpCAM positive Cancer.
- Conditions
- Colon Cancer, Esophageal Carcinoma, Pancreatic Cancer, Prostate Cancer
- Trial name
- CARTEPC (NCT03013712)
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Chengdu Medical College
Colon Cancer, Lung Cancer
Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer
The purpose of CLOVER is to utilize Epic Healthy Planet to increase adherence to United States Preventive Services Task Force (USPSTF) and Centers for Disease Control and Prevention (CDC) recommendations in adults age 50 and…
- Conditions
- Colon Cancer, Lung Cancer, Tobacco Use Cessation, Obesity
- Trial name
- CLOVER (NCT04540081)
- Testing
- Epic Healthy Planet Population Health Module
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- University of California, Davis
Liver Cancer, Hepatocellular Carcinoma
Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
Cirrhotic patients undergoing hepatic resection have a mortality rate near 10%, and 30 to 70% of them develop severe complications. These failures are mainly due to hepatic insufficiency.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cirrhosis, Liver Fibrosis
- Trial name
- IMPACT (NCT00151671)
- Testing
- Oral Impact®
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Rennes University Hospital
Liver Tumor, Hepatocellular Carcinoma
NeuWave Microwave Ablation HCC China Study
This is a single-arm, prospective, multicenter, study. Individuals who are assessed for microwave (MW) ablation of HCC in accordance with their institution's standard of care (SOC), who meet study entry criteria and sign the…
- Trial name
- NW (NCT03783871)
- Testing
- Microwave ablation
- Where
- 4 sites in China
- Volunteers
- 135 people
- Sponsor
- Ethicon, Inc.
Hepatocellular Carcinoma
A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC
The purpose of this study is to evaluate the effect of the anti-programmed death 1 (PD-1) agent nivolumab following selective internal radiation therapy (SIRT) for patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NASIR-HCC (NCT03380130)
- Testing
- Nivolumab, SIR-Spheres
- Where
- 9 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Cholangio Carcinoma
Treatment for Bile Duct Cancer in the Liver
The current standard treatment of inoperable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) is chemotherapy, which is of limited efficacy.
- Trial name
- NCT02167711
- Testing
- SIRT Yttrium-90
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- Chinese University of Hong Kong
Liver Carcinoma
Hepatocellular Carcinoma Treated With Iodine-125 Implantation
To prospectively evaluate whether use of combined radiofrequency ablation (RFA) and percutaneous iodine-125 (125I) seeds implantation results in better survival compared with use of RFA alone in patients with hepatocellular…
- Trial name
- NCT01717729
- Testing
- Radiofrequency Ablation, iodine
- Volunteers
- 136 people
- Sponsor
- The Second People's Hospital of GuangDong Province
Hepatocellular Carcinoma
Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
This surveillance's objectives are: 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Factors considered to have effect to safety and effectiveness
- Trial name
- NCT02269995
- Testing
- E7040
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Eisai Co., Ltd.
Circulating Tumor DNA, Hepatocellular Carcinoma Non-resectable
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
Cohort study to assess the impact of ctDNA detection in the follow-up and management of patients with hepatocellular carcinoma treated by TACE
- Conditions
- Circulating Tumor DNA, Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization
- Trial name
- Mona-Lisa (NCT05390112)
- Testing
- DNA
- Where
- France
- Volunteers
- 167 people
- Sponsor
- University Hospital, Rouen
Advanced Hepatocellular Carcinoma, HCC
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
This is a Phase 2 Study of PD-0332991 in the treatment of patients with Advanced Hepatocellular Carcinoma (HCC), a type of adenocarcinoma and the most common type of liver tumor.
- Conditions
- Advanced Hepatocellular Carcinoma, HCC, Liver Cancer
- Trial name
- NCT01356628
- Testing
- PD-0332991
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hepatocellular Carcinoma
HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with Programmed Cell Death Protein-1 (PD-1) antibody compared with HAIC plus sorafenib in patients with…
- Trial name
- NCT03780634
- Testing
- HAIC, PD-1 antibody, Sorafenib
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Lung Cancer, Hepatocellular Carcinoma
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
- Conditions
- Lung Cancer, Hepatocellular Carcinoma, Solid Tumor
- Trial name
- NCT04952272
- Testing
- CpG-ODN
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Liver Cancer
Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies
This research study is studying the TriNav ("TriSalus") for increasing delivery of chemotherapeutic agents delivered trans-arterially to intermediate stage Hepatocellular Carcinoma ("HCC") (Barcelona Clinic Liver Cancer (BCLC)…
- Trial name
- NCT02853500
- Testing
- TriNav, Traditional Delivery, Doxorubicin
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute